Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
RZLT · against 407 other Healthcare companies of similar size
Ranked #257 of 408 · scores higher than 11% of peers
Bars: peers in each 10-point band of the valuation score152 peers with a valuation score of 0–9, including RZLT · Click a bar to see the companies
Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | RZLT | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 394 reported | -18.7% | 0.0% | 19% | 30% | |
| EBITDA yieldHigher is better · 413 reported | -29.0% | 3.0% | 12% | 50% | |
| Free cash flow yieldHigher is better · 194 reported | -18.9% | -8.5% | 28% | 20% | |
| Book yieldHigher is better · 405 reported | 26.0% | 50.1% | 24% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 89.9B JPY (≈$611M) | 99 | 68 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 1 | 29.0B JPY (≈$197M) | 99 | 56 | |
| 257 | 427M USD | 8 | 7 | |
| 257 | 421M USD | 8 | 52 | |
| 257 | 474M USD | 8 | 25 | |
| 257 | 504M USD | 8 | 24 | |
| 257 | 388M USD | 8 | 36 | |
| 257 | 730M USD | 8 | 11 | |
| 257 | 468M USD | 8 | 40 | |
| 257 | 519M USD | 8 | 22 | |
| 257 | 223M USD | 8 | 34 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score